Free Trial
NASDAQ:CELU

Celularity Q3 2024 Earnings Results & Report

Celularity logo
$0.61 -0.02 (-2.71%)
As of 02:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Celularity reported Q3 2024 earnings on December 6, 2024. The company reported EPS of -$0.73.

Earnings Announcement Details

Quarter
Q3 2024
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
6:00 PM ET

Celularity EPS Results

Actual EPS
-$0.73
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 6 quarters

Celularity Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Celularity Q3 2024 Earnings FAQ

Celularity (NASDAQ:CELU) reported earnings of -$0.73 per share for Q3 2024. The report was announced on Friday, December 6, 2024.

Celularity Earnings Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease.

The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy.

Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. Its work focuses on developing and manufacturing placenta-derived products for clinical and commercial use.

View Celularity Profile